Review

British Journal of Cancer (2001) 84, 1437–1442. doi:10.1054/bjoc.2001.1819 www.bjcancer.com
Published online 29 May 2001

Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer

R C F Leonard1

1Department of Clinical Oncology, Western General Hospital, Edinburgh, UK

Received 21 August 2000; Revised 30 January 2001; Accepted 20 February 2001.

Top

Abstract

Although drugs such as the taxoids and vinorelbine have increased the options available for anthracycline-resistant metastatic breast cancer, new therapeutic options are needed, particularly for taxoid-refractory tumours. Increasing emphasis is being placed on the development of oral agents, which many patients prefer provided efficacy is not compromised, particularly if the oral agents are less toxic than current intravenous agents. Capecitabine, a new, oral fluoropyrimidine, mimics continuous infusion 5-FU and is activated preferentially at the tumour site. Phase II studies of capecitabine have demonstrated encouraging response rates in patients with few further treatment options (20% response with an additional 43% achieving stable disease in paclitaxel-refractory patients; 36% response with a further 23% achieving stable disease in anthracycline-refractory patients). In addition, a randomized, phase II trial demonstrated a response rate of 30% (95% Cl: 19–43%) with capecitabine as first-line treatment for metastatic breast cancer, compared with 16% (95% Cl: 5–33%) in patients receiving low-dose CMF. These trials also showed that capecitabine has a favourable safety profile typical of infused fluoropyrimidines. Both alopecia and myelosuppression were rare. Capecitabine may therefore provide an effective, well-tolerated and convenient alternative to intravenous cytotoxic agents, not only in taxoid-resistant patients, but also in anthracycline-resistant metastatic breast cancer or as first-line therapy. Furthermore, the low incidence of myelosuppression makes capecitabine an attractive agent for incorporation into combination regimens with agents such as epirubicin/doxorubicin, the taxoids and vinorelbine. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords:

breast cancer, anthracyclines, capecitabine, 5-FU, taxoids, vinorelbine, oral

Top

References

  1. Aapro M (2000) First-line capecitabine treatment for metastatic breast cancer (MBC): updated data from a randomised phase II trial. Proc ICACT, S4–10
  2. Archer CD, Lowdell C, Sinnett HD, English J, Khan S and Coombes RC (1998) Docetaxel: response in patients who have received at least two prior chemotherapy regimens for metastatic breast cancer. Eur J Cancer 34: 816–819
  3. Bishop JF, Dewar J, Toner GC, Tattersall MHN, Oliver IN, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J and Stephenson J (1997) Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New Zealand. Oncology (Huntingt) 11 (4 Suppl 3): 19–23
  4. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS and Griffin T (1999) A multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17: 485–493 | PubMed | ISI | ChemPort |
  5. Budman DR, Meropol NJ, Reigner B, Creavan PJ, Lichtman SM, Berghorn E, Behr J, Gordon R, Osterwalder B and Griffin T (1998) Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 16: 1795–1802 | PubMed | ISI | ChemPort |
  6. Carlson RW (1998) Quality of life issues in the treatment of metastatic breast cancer. Oncology (Huntingt) 12 (3 Suppl 4): 27–31
  7. Cassidy J, Dirix L, Bissett D, Reigner B, Griffin T, Allman D, Osterwalder B and Van Oosterom AT (1998) A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin Cancer Res 4: 2755–2761 | PubMed | ISI | ChemPort |
  8. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Durate R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Gonzalez Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M and Riva A for the 303 Study Group (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17: 2341–2354 | PubMed | ISI | ChemPort |
  9. D'Andrea GM and Seidman AD (1997) Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects. Semin Oncol 24(Suppl 13): S13–27–S13–44 | PubMed | ChemPort |
  10. Degardin M, Bonneterre J, Hecquet B, Pion JM, Adenis A, Horner D and Demaille A (1994) Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 5: 423–426 | PubMed | ChemPort |
  11. DeMario MD and Ratain MJ (1998) Oral chemotherapy: rationale and future directions. J Clin Oncol 16: 2557–2567 | PubMed | ISI | ChemPort |
  12. Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, Garcia-Giralt E, Keiling R, Namer M, Closon MT, Goudier MJ, Chollet P, Lecourt L and Montcuquet P (1993) Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11: 1245–1252 | PubMed | ISI | ChemPort |
  13. Hansen R, Quebbeman E, Beatty P, Ritch P, Anderson T, Jenkins D, Frick J and Ausman R (1987) Continuous 5-fluorouracil infusion in refractory carcinoma of the breast. Breast Cancer Res Treat 10: 145–149 | PubMed | ISI | ChemPort |
  14. Hortobagyi GN and Piccart-Gebhart MJ (1996) Current management of advanced breast cancer. Semin Oncol 23(Suppl 11): 1–5 | PubMed | ISI | ChemPort |
  15. Huan S, Pazdur R, Singhakowinta A, Samal B and Vaitevicius VK (1989) Low-dose continuous infusion 5-fluorouracil. Evaluation in advanced breast cancer. Cancer 63: 419–422
  16. Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F and Ishitsuka H (1998a) Tumour selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55: 1091–1097 | Article | PubMed | ISI | ChemPort |
  17. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N and Ishitsuka H (1998b) Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumours in human cancer xenografts. Cancer Res 58: 685–690 | PubMed | ISI | ChemPort |
  18. Jabboury K, Holmes FA and Hortobagyi G (1989) 5-fluorouracil rechallenge by protracted infusion in refractory breast cancer. Cancer 64: 793–797
  19. Johnson MR, Hageboutros A, Wang K, High L, Smith JB and Diasio RB (1999) Life-threatening toxicity in a dihydropyrimidine dehydrogenase deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 5: 2006–2011 | PubMed | ISI | ChemPort |
  20. Jones S, Winer E, Vogel C, Laufman L, Hutchins L, O'Rourke M, Lembersky B, Budman D, Bigley J and Hoeneker J (1995) Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 13: 2567–2574
  21. Judson IR, Beale PJ, Trigo JM, Aherne W, Crompton T, Jones D, Bush E and Reigner B (1999) A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug. Invest New Drugs 17: 453–460
  22. Khoury P, Villalona-Calero M, Blum J, Diab S, Elledge R, Kraynak M, Moczygemba J, Kromelis P, Morales I, Brown C, Griffin T, Von Hoff D and Rowinsky E (1998) Phase I study of capecitabine in combination with paclitaxel in patients with previously treated metastatic breast cancer. Proc Am Soc Clin Oncol 17: 206a (Abstract 793)
  23. Liu G, Franssen E, Fitch M and Warner E (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15: 110–115 | PubMed | ISI | ChemPort |
  24. Livingston RB, Ellis GK, Gralow JR, Williams MA, White R, McGuirt C, Adamkiewicz BB and Long CA (1997) Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 15: 1395–1400 | PubMed | ISI | ChemPort |
  25. Lu Z, Zhang R, Carpenter JT and Diasio RB (1998) Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res 4: 325–329 | PubMed | ChemPort |
  26. Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, Reginer B, Griffin T, Kaye S and Verweij J (1998) Phase I and pharmacologic study of intermittent twice daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 16: 2977–2985 | PubMed | ISI | ChemPort |
  27. Miwa M, Nishida UM, Ishikawa ST, Mori K, Umeda SI and Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34: 1274–1281 | Article | PubMed | ISI | ChemPort |
  28. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M and Aapro M for the 304 Study GROUP (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 17: 1413–1424 | PubMed | ISI | ChemPort |
  29. Ng JS, Cameron DA and Leonard RCF (1994) Infusional 5-fluorouracil in breast cancer. Cancer Treat Rev 20: 357–364
  30. O'Reilly SM, Moiseyenko V, Talbot DC, Gordan RJ, Griffin T and Osterwalder B (1998) A randomized phase II study of Xeloda™ (capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy. Proc Am Soc Clin Oncol 17: 163a (Abstract 627)
  31. O'Shaughnessy J, Vukelja S, Moiseyenko V, Miles D, Cervantes G, Chan NAVARROC, Mauriac L, Van Hazel G, Lui W-Y, Ayoub J-P, Rizel S, Osterwalder B, Rutman O and Leonard R (2000) Results of a large phase III trial of Xeloda®/Taxotere®combination therapy vs Taxotere®monotherapy in metastatic breast cancer (MBC) patients, Poster presented at the San Antonio Breast Cancer Symposium, San Antonio, USA; (Abstract 381).
  32. Pronk L, Vasey AP, Sparreboom A, Reigner B, Planting ASTh, Gordon RJ, Osterwalder B, Verweij J and Twelves C (2000) A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br J Cancer 83: 22–29 | Article | PubMed | ISI | ChemPort |
  33. Ragaz J, Campbell C, Gelmon K, Tolcher T, Bryce C and O'Reilly S (1997) Can patients with metastatic breast cancer (MBC) pretreated with cyclophosphamide (C), anthracyclines (A) or Taxol (Tax) respond to infusions of 5-FU (FUI)? Rationale for FUI-containing chemotherapy (CT) regimens. Breast Cancer Res Treat 46: 95 (Abstract 411)
  34. Ray-Coquard I, Biron P, Bachelot T, Guastalla JP, Catimel G, Merrouche Y, Droz JP, Chauvin F and Blay JY (1998) Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline-and/or paclitaxel-containing regimens. Cancer 82: 134–140 | Article | PubMed | ISI | ChemPort |
  35. Roché H, Fumoleau P, Tresca P, Pinon G, Serin D, Marie FN, Delgado M and Belpomme D (1990) Vinorelbine, a new active drug in breast carcinoma: results of an ARTAC phase II trial. Ann Oncol 1(Suppl): 36
  36. Romero A, Rabinovich MG, Vallejo CT, Perez JE, Rodriguez R, Cuevas MA, Machiavelli M, Lacava JA, Langhi M, Romero Acuna L, Amato S, Barbieri R, Sabatini C and Leone BA (1994) Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 12: 336–341 | PubMed | ChemPort |
  37. Schiff PB and Horwitz SB (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561–1565 | Article | PubMed | ChemPort |
  38. Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E and Reigner B (2000) Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol 45: 291–297 | Article | PubMed | ISI | ChemPort |
  39. Seidman AD, Tiersten A, Hudis C, Gollub M, Barrett S, Yao T-J, Lepore J, Gilewski T, Currie V, Crown J, Hakes T, Baselga J, Sklarin N, Moynihan ME, Tong W, Egorin M, Kearns C, Spriggs D and Norton L (1995) Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 13: 2575–2581 | PubMed | ISI | ChemPort |
  40. Valero V, Jones SE, Von Hoff DD, Booser DJ, Mennel RG, Ravdin PM, Holmes FA, Rahman Z, Schottstaedt MW, Erban JK, Esparza-Guerra L, Earhart RH, Hortobagyi GN and Burris HA 3RD (1998) A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 16: 3362–3368 | PubMed |
  41. Van Cutsem E, Findlay M, Osterwalder B, Kocha W, Dalley D, Pazdur R, Cassidy J, Dirix L, Twelves C, Allman D, Burger HU and Verweij J (2000) Capecitabine (XelodaTM), an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 18: 1337–1345 | PubMed | ISI | ChemPort |
  42. Villalona-Calero MA, Weiss GR, Burris HA, Kraynak M, Rodrigues G, Drengler RL, Eckhardt SG, Reigner B, Moczygemba J, Burger HU, Griffin T, Von Hoff DD and Rowinsky EK (1999) Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. J Clin Oncol 17: 1915–1925 | PubMed | ISI | ChemPort |
  43. Weber BL, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J and Hohneker J (1995) Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 13: 2722–2730 | PubMed | ISI | ChemPort |